TrialBone marrow transplantation2014

Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial.

S R Solomon et al.PubMed ↗Publisher ↗

No numbers read from the abstract.